Research and development of polypeptide drugs

In the past, the pharmaceutical industry did not pay enough attention to peptide drugs With the approval of 6 peptide drugs by FDA in 2012, and the technical barriers in research and development, production and other aspects of these drugs are between small molecules and biological drugs, the industry believes that the research and development of peptide drugs may usher in a new round of research upsurge, and more and more drug companies can invest in it in the future In this case, what is the prospect of peptide drug market (including generic and innovative drugs) in China? Netizens' frenzied fist response: foreign peptide preparation companies are basically innovative drug companies, such as Eli Lilly's exenatide, etc., and Tyva and other generic drug companies have also stepped in, but they have not performed well, mainly restricted by raw materials The domestic polypeptide manufacturers are Shenzhen Hanyu, Hainan Zhonghe, etc., but most of them are generic drugs In terms of technology, China has done a good job in the imitation of polypeptides with simple structure, while there is a certain gap in quality control, yield and cost in the synthesis of complex polypeptides compared with foreign countries Netizen kai67419 responded: the prospect of such generic drugs in China is relatively broad At present, there are no more than 5 manufacturers, involving more than 10 varieties At present, the biggest defect is that there is no relevant platform for the technical review of peptide compounds Therefore, if pharmaceutical companies intend to develop, they need to establish a relevant technical platform through the interaction between the application of small molecular peptides and the drug review center, so that further work can be done, which is the significance of the imitation work As for innovation, it is suggested to make macromolecular peptide directly Response from netizen luming525: new drugs dare not say that the most striking thing in the research and development of generic drugs is their low-cost R & D investment and the therapeutic effect of standing up and seeing the shadow, while peptide drugs do not occupy the same proportion, so in the past few years, pharmaceutical companies will not fall in this direction In recent two years, the increase in popularity is more like there is no better choice In addition, in the preparation production, the cost makes the pharmaceutical enterprises lack of market competitiveness, injection is not as good as oral, in the case of small molecular medicine competitors, peptide drugs have no advantage, and the preparation cost of pre filling is even higher Netizen sbc123 responded: domestic R & d still has blind following Excellent enterprises follow the trend of foreign countries, and second-class enterprises learn from domestic excellent enterprises Therefore, any hot research topic will cause a "swarm" of pharmaceutical enterprises In fact, peptide drugs are not a hot topic in foreign countries, but more rationally regarded as a kind of niche products In addition, at present, there are no series of heavy-duty product groups for small and large polypeptide molecules, most of which are point flowering and have no surface effect, so the research and development is not enthusiastic (the above opinions come from a well-known forum in China)